Cancer-Associated Thrombosis: Anticoagulation Strategies and Emerging Therapies

Review in Current Practice in Venous Thromboembolism is a two-day live virtual conference dedicated to advancing the understanding and management of VTE. Join leading experts as they explore emerging science, evolving risk stratification tools, and modern therapeutic strategies across diverse patient populations. This focused update on thrombosis care offers clinicians practical, evidence-based insights to improve outcomes across inpatient, outpatient, and high-risk settings.
Key Topics
Innovations in VTE: Advances in diagnostics, risk prediction, and the future of thrombosis care
Inpatient to Post-Discharge: Continuum of VTE prevention in hospitalized medical patients
Risk Stratification 2.0: Newer techniques using biomarkers & imaging advancements
Specialised care: including VTE management in women and the elderly
Procedural Interventions in DVT: What every physician should know about IVC filters and venous stents
Cancer-Associated Thrombosis: Personalized anticoagulation and new therapy frontiers
Managing APLA Syndrome: From diagnosis to long-term thrombosis prevention
This comprehensive review will help refine your clinical decision-making in VTE care. Stay updated, stay prepared-Register now to secure your spot.

RCP VTE Day 2

Many patients face a high risk of VTE both during hospitalization and in the vulnerable post-discharge phase. Chaired by Dr Vivekanand with keynote by Dr Kumud Rai, this session will explore evidence-based inpatient protocols, transitional care strategies, and best practices to ensure continuous protection against VTE-related complications.

Continuum of VTE Care: Inpatient strategies for medical patients and Post-Discharge protection

RCP VTE Day 1

Principal Director Vascular Surgery, Max Healthcare - NCR, Former Councillor, European Society for Vascular Surgery, New Delhi

The Review of Current Practices (RCP) on venous thromboembolism (VTE) kicks off with a focused and clinically rich Day 1, chaired by Lt Gen (Dr.) Velu Nair (Retd.). Designed for busy clinicians, the evening features 3 expert-led sessions that lay the foundation for evidence-based VTE management.

The agenda begins with an overview of contemporary approaches, followed by a discussion of thromboprophylaxis and risk stratification, emphasizing translation of evidence into real-world clinical decision-making. This is complemented by a session on catheter-related thrombosis, bringing in interventional and surgical perspectives.

The day culminates in an in-depth panel discussion, focusing on personalizing VTE management in complex “grey zone” populations, including obesity, bleeding risk, renal dysfunction, and young adults.

With interactive elements such as live polls, audience Q&A, and case-based insights, Day 1 sets the stage for a practical, nuanced understanding of VTE management. Participants will also engage through pre–post assessments, with certificates awarded upon completion.

RCP VTE 2026 - Day 1

This session includes a comprehensive evidence-based strategies for VTE thromboprophylaxis and risk stratification, translating current guidelines into real-world clinical decision-making. The session examines validated risk scoring tools, patient selection criteria, and the challenges of implementing prophylaxis protocols across diverse clinical settings.

Interventional vs Medical Management of VTE: Are We Choosing the Right Patients?

Day 2 of the Review of Current Practices (RCP) on venous thromboembolism (VTE) builds on foundational concepts with a sharper focus on high-risk scenarios and evolving treatment paradigms. Chaired by Lt Gen (Dr.) Velu Nair (Retd.), the day features 4 expert-led sessions designed to refine clinical decision-making.

The evening begins with a recap of key Day 1 insights, followed by a keynote by Dr. Velu Nair on cancer-associated thrombosis, addressing treatment complexities in high-risk patients. Then presents emerging evidence in anticoagulation, with insights from the COBRRA trial and its clinical implications.

Subsequent sessions include rationalizing the use of DOACs, LMWH, and oral anticoagulants, and a discussion on selecting between interventional and medical management strategies in VTE.

The program concludes with closing remarks and key takeaways, reinforcing practical application. As with Day 1, the format remains highly interactive with live polls, audience engagement, and knowledge assessments, ensuring meaningful learning outcomes for participants.

RCP VTE 2026 - Day 2

Dr Velu Nair navigates the complex landscape of cancer-associated thrombosis (CAT), one of the most clinically challenging subsets of VTE. The session addresses risk stratification in oncology patients, the comparative efficacy and safety of DOACs versus LMWH, management in the context of thrombocytopenia and drug interactions, and practical decision frameworks for high-risk patients.

Cancer‑Associated Thrombosis: Navigating Treatment Decisions in High‑Risk Patients

This session includes a focused analysis of emerging evidence in VTE anticoagulation, with particular attention to the landmark COBRRA trial : a pivotal head-to-head comparison of rivaroxaban versus apixaban in patients with acute VTE. The session examines trial design, key outcomes on bleeding risk, and the implications of these findings for anticoagulant selection in everyday clinical practice.

Dr. Kumud Mohan Rai

9

2.1k

85.1k

4.8

Upcoming Sessions

Sessions Taken

919

4.7

844

4.8

1.1k

4.7

1k

4.7